about
Antifungal Therapy in Hematopoietic Stem Cell Transplant RecipientsCombination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data.Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey.Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation.BMT: Bone Marrow Transplant Associated Thrombotic Microangiopathy.Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.Acute myositis following autologus bone marrow transplantation (BMT).Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis.Derivation and validation of a scoring system to identify patients with bacteremia and hematological malignancies at higher risk for mortality.Allogenic stem cell transplantation following non-myeloablative conditioning regimens as adoptive immunotherapy in patients with hematological malignancies.Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry.Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, AsPrimary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO).Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.Recent Advances in Bone Marrow Transplantation from Unrelated Volunteer Donors.Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations.Reviewing the importance and evolution of fungal infections and potential antifungal resistance in haematological patients.Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use.Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients.Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report.SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.Management of carbapenem-resistant K. pneumoniae in allogenic stem cell transplant recipients: the Turin bundle.The reversed halo sign as the initial radiographic sign of pulmonary zygomycosis.Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey.Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey.Umbilical cord blood stem cell transplantation.Viral infections in patients with hematological malignancies.The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors.Incidence, risk factors and outcome of pre engraftment Gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey.Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).Ruxolitinib in steroid refractory graft-vs.-host disease: a case reportMultidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies.
P50
Q28080147-644C415C-EB91-4DB9-8275-CD5E84E233F7Q30873926-5C67A330-D34D-4949-9B81-628B1C9A4B54Q30884751-AEDE0ED0-2734-4C2A-94AF-5963EB1F4609Q33335309-A255E80F-A802-42E2-8820-AA737FD24E9CQ33337686-8E96CC63-7E1B-4895-9185-5C57D1E3F7C5Q33375027-C159E81F-19F9-427E-8821-B54FC9A1C3D0Q33502359-503E89B3-A575-4678-88DB-97453F433F37Q34448617-E3E4082F-2B56-46E1-A0AC-5095C2FB4627Q34525373-AFF8EA4A-52C6-4E9D-8A30-4314372A7D63Q34975253-7DB59A27-C7B4-4112-880F-291C398C56F2Q36715906-DC4A6C70-DDB4-46B5-9327-45431685FAAFQ37139319-2C4726CD-6836-4B8D-B4F5-EB6B80A44690Q37176871-B760DA82-A57C-4276-B50A-0DCB250CF9A4Q37851519-F81D40AE-EB67-4273-AB6C-0D2C0ECA6C8EQ37925817-3C08DED7-EB6D-4DC5-8E15-8EEC7DECFA37Q38049498-27C18195-0DBE-4739-95CF-404AED284D72Q38192322-BC4BED70-2C4F-4162-8D07-99FA538AD53CQ38221844-DB3E1656-0E53-4491-8D53-EB53C7258573Q38797660-0F27E455-7D66-4429-89D3-7BE25185F96AQ38894371-070E7EFC-EFEA-4C02-B3BB-E9DCA367B211Q38967328-F3B09950-0124-47F4-B2FC-D9254ADFFD3AQ39008488-02F1E1E6-4A6E-4BCB-B66C-24C1DC456BF1Q39196802-EFE7F9B5-812D-450C-B0A6-F73476B62CF0Q39283415-B213257A-77AC-427F-80A4-6A34DE8B3C53Q40067918-ABE48DE2-95FE-4C34-9E2E-4D0D1FE26CD0Q40125779-831A8BC1-C509-4F28-80E5-37CD662C0FFCQ40210945-D99AA6F9-173D-41AA-802F-3572E9CC42DCQ40268252-3F077088-CB71-43B8-AF56-E55B0538DF67Q40319358-08855B5F-8025-43BD-AFBE-F4BD0B2E6E64Q40394731-496CE6D4-6E64-4B28-BBB0-CD133D831090Q40475236-F4392485-F35F-48BA-8FC2-E7ADB6F9F96AQ40493201-5A271A3B-96EC-46EE-9B77-30A22EEE2841Q40500618-D3B92389-DE23-4BE3-BF02-0EC19D4DFF7FQ40623753-6718DD9F-F15F-439B-9BFB-AA0CB0196229Q40817293-E6BF53E6-2F2E-45C3-8D03-BD6E36538AA3Q41442242-36DC5F02-A241-424B-9D83-40D2E761EE4AQ41987093-90397FC4-2601-4782-8F17-69B8A10D4DA6Q42223864-AF284F24-C2BA-4A9C-8369-ADCD9BA507C2Q42255208-9CEF9FF0-CB4A-4ECD-B83E-BD85B7135A81Q42558452-8768E19B-FA32-4354-8C2C-D74069F2A3D8
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alessandro Busca
@ast
Alessandro Busca
@en
Alessandro Busca
@es
Alessandro Busca
@nl
Alessandro Busca
@sl
type
label
Alessandro Busca
@ast
Alessandro Busca
@en
Alessandro Busca
@es
Alessandro Busca
@nl
Alessandro Busca
@sl
prefLabel
Alessandro Busca
@ast
Alessandro Busca
@en
Alessandro Busca
@es
Alessandro Busca
@nl
Alessandro Busca
@sl
P106
P21
P31
P496
0000-0001-5361-5613
P569
2000-01-01T00:00:00Z